Literature DB >> 21878509

Immunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells.

Tobias Deuse1, Martina Seifert, Neil Phillips, Andrew Fire, Dolly Tyan, Mark Kay, Philip S Tsao, Xiaoqin Hua, Joachim Velden, Thomas Eiermann, Hans-Dieter Volk, Hermann Reichenspurner, Robert C Robbins, Sonja Schrepfer.   

Abstract

Human embryonic stem cells (hESCs) can serve as a universal cell source for emerging cell or tissue replacement strategies, but immune rejection of hESC derivatives remains an unsolved problem. Here, we sought to describe the mechanisms of rejection for naïve hESCs and upon HLA class I (HLA I) knockdown (hESC(KD)). hESCs were HLA I-positive but negative for HLA II and co-stimulatory molecules. Transplantation of naïve hESC into immunocompetent Balb/c mice induced substantial T helper cell 1 and 2 (Th1 and Th2) responses with rapid cell death, but hESCs survived in immunodeficient SCID-beige recipients. Histology revealed mainly macrophages and T cells, but only scattered natural killer (NK) cells. A surge of hESC-specific antibodies against hESC class I, but not class II antigens, was observed. Using HLA I RNA interference and intrabody technology, HLA I surface expression of hESC(KD) was 88%-99% reduced. T cell activation after hESC(KD) transplantation into Balb/c was significantly diminished, antibody production was substantially alleviated, the levels of graft-infiltrating immune cells were reduced and the survival of hESC(KD) was prolonged. Because of their very low expression of stimulatory NK ligands, NK-susceptibility of naïve hESCs and hESC(KD) was negligible. Thus, HLA I recognition by T cells seems to be the primary mechanism of hESC recognition, and T cells, macrophages and hESC-specific antibodies participate in hESC killing.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21878509     DOI: 10.1242/jcs.087718

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  9 in total

Review 1.  Immunological Issues After Stem Cell-Based β Cell Replacement.

Authors:  Valeria Sordi; Silvia Pellegrini; Lorenzo Piemonti
Journal:  Curr Diab Rep       Date:  2017-09       Impact factor: 4.810

Review 2.  Human pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair.

Authors:  Matthew E Hartman; Dao-Fu Dai; Michael A Laflamme
Journal:  Adv Drug Deliv Rev       Date:  2015-05-14       Impact factor: 15.470

Review 3.  Immunogenicity of pluripotent stem cells and their derivatives.

Authors:  Patricia E de Almeida; Julia D Ransohoff; Abu Nahid; Joseph C Wu
Journal:  Circ Res       Date:  2013-02-01       Impact factor: 17.367

4.  Characterization and therapeutic potential of induced pluripotent stem cell-derived cardiovascular progenitor cells.

Authors:  Ali Nsair; Katja Schenke-Layland; Ben Van Handel; Denis Evseenko; Michael Kahn; Peng Zhao; Joseph Mendelis; Sanaz Heydarkhan; Obina Awaji; Miriam Vottler; Susanne Geist; Jennifer Chyu; Nuria Gago-Lopez; Gay M Crooks; Kathrin Plath; Josh Goldhaber; Hanna K A Mikkola; W Robb MacLellan
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

Review 5.  The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives.

Authors:  Xin Liu; Wenjuan Li; Xuemei Fu; Yang Xu
Journal:  Front Immunol       Date:  2017-06-02       Impact factor: 7.561

6.  Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Authors:  Hocine R Hocine; Hicham E L Costa; Noemie Dam; Jerome Giustiniani; Itziar Palacios; Pascale Loiseau; Armand Bensussan; Luis R Borlado; Dominique Charron; Caroline Suberbielle; Nabila Jabrane-Ferrat; Reem Al-Daccak
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

7.  Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1.

Authors:  Vanessa Kruse; Carina Hamann; Sebastian Monecke; Lukas Cyganek; Leslie Elsner; Daniela Hübscher; Lutz Walter; Katrin Streckfuss-Bömeke; Kaomei Guan; Ralf Dressel
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

8.  Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer.

Authors:  Pere Puig; Nadina Erill; Marta Terricabras; Isaac Subirana; Judit González-García; Adrià Asensi-Puig; Michael J Donovan; Lourdes Mengual; M Teresa Agulló-Ortuño; Mireia Olivan; Antonio Alcaraz; José A López-Martín; Inés de Torres; José Luis Rodríguez-Peralto; Alfredo Rodríguez-Antolín; Juan Morote; Víctor González-Rumayor
Journal:  BMC Res Notes       Date:  2019-01-30

Review 9.  Generation of universal and hypoimmunogenic human pluripotent stem cells.

Authors:  Qingsong Ye; Tzu-Cheng Sung; Jen-Ming Yang; Qing-Dong Ling; Yan He; Akon Higuchi
Journal:  Cell Prolif       Date:  2020-11-11       Impact factor: 6.831

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.